Sudo Biosciences, a Carmel, IN-based biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, raised $116M in Series B funding.
The round, which brought the total amount to $157M, was led by Enavate Sciences and TPG, which is investing in the company through TPG Life Sciences Innovations and The Rise Fund, with participation from Sanofi Ventures, Surveyor Capital (a Citadel company), Monograph Capital, and Eventide Asset Management as well as existing investors Frazier Life Sciences and Velosity Capital.
The company intends to use the funds to advance two investigational TYK2 candidates into the clinic next year.
Led by CEO Scott Byrd, Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel medicines to transform patients’ lives. Its programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions. Its pipeline of next generation TYK2 inhibitors includes a brain-penetrant candidate for the treatment of multiple sclerosis and neurodegenerative diseases with underlying neuroinflammation and a topical candidate for immune-mediated dermatologic diseases.
FinSMEs
20/12/2023